45 results about "Pigmented retinal epithelium" patented technology

The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.

The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serum-containing medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.

A device for fusing two or more tissues is disclosed. The device comprises a hand held probe comprising a fluid receiving opening, a channel and an outlet in fluid communication whereby fluid passes through the channel and exits the outlet where it is directed to at least one of the two or more tissues and / or a space in-between. A disruptive emitter comprised on the probe which emits a force sufficient to fuse the two or more tissues. The device finds particular application to treatment of a detached retina by fusing the retina and the retinal pigmented epithelium. A method of fusing two or more tissues including a retina and underlying retinal pigmented epithelium is also disclosed.

The invention relates to the field of cellular biology, in particular to a retinal pigment epithelial cell and a preparation method and application thereof. The retinal pigment epithelial cell expresses MITF and ZO-1. The preparation method of the retinal pigment epithelial cell comprises the following steps of S1: culturing human pluripotent stem cells; S2: differentiating the human pluripotent stem cells obtained in S1 into retinal pigment epithelial precursor cells; S3: differentiating the retinal pigment epithelial precursor cells obtained in S2 into immature retinal pigment epithelial cells; and S4: differentiating the immature retinal pigment epithelial cells obtained in S3 to obtain retinal pigment epithelial cells. The preparation method can differentiate pluripotent stem cells rapidly, efficiently and simply to obtain retinal pigment epithelial cells. In addition, no system containing serum or a serum substitute is used in the preparation method provided by the invention. Thedifferentiation efficiency is high and the differentiation effect is stable. The purification method is simple and the obtained cell has high purity.

Tissue replacement implants are disclosed that include polarized retinal pigment epithelial cells on a poly(lactic-co-glycolic acid) (PLGA) scaffold, wherein the PLGA scaffold is 20-30 microns in thickness, has a DL-lactide / glycotide ratio of about 1:1, an average pore size of less than about 1 micron, and a fiber diameter of about 150 to about 650 nm. Also disclosed are methods of treating a subject with a retinal degenerative disease, retinal or retinal pigment epithelium dysfunction, retinal degradation, retinal damage, or loss of retinal pigment epithelium. These methods include locally administering to the eye of the subject the tissue replacement implant. In further embodiments, methods are disclosed for producing the tissue replacement implant.

The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1000 bp having at least 80% identity to the sequence of SEQ ID NO:1, wherein the isolated nucleic acid molecule specifically leads to the expression in cells of the retinal pigment epithelium of a gene when operatively linkedto a nucleic acid sequence coding for the gene.

Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and / or CD90 positive cells from a starting population of RPE cells.

The present application relates to an isolated nucleic acid molecule comprising a nucleotide sequence encoding a CAG promoter, a nucleotide sequence encoding a first protein, a nucleotide sequence encoding a second protein and a nucleoside encoding a BGH signal site An acid sequence, wherein the first protein and the second protein are each differently selected from the group consisting of CYP4V2 protein and RdCVF protein, wherein the nucleotide sequence encoding the CYP4V2 protein comprises the nucleotide sequence of SEQ ID NO:168, The nucleotide sequence encoding the RdCVF protein comprises the nucleotide sequence of SEQ ID NO:167. The present application also relates to the use of the nucleic acid molecule in the preparation of a medicament for treating, alleviating and / or preventing diseases or conditions associated with retinal pigment epithelium (RPE) atrophy.

The invention provides a gene therapy drug for eye-specific expression of retinal pigment epithelium 65 (RPE65) for treating Leber congenital amaurosis. The vector contains CMV enhancer, human RPE65 gene promoter, human RPE65 gene coding region and intron composition sequence, polyA sequence and artificially spliced ​​RPE65 gene enhancer. The recombinant vector is mediated by single- and / or double-stranded adeno-associated virus (AAV) vectors, including but not limited to adeno-associated virus type 9 (AAV9).

The invention relates to the technical field of biomedical gene therapy, and discloses a nucleotide sequence encoding human receptor tyrosine kinase Mer and its application. The nucleotide sequence of the present invention has ≥95% identity with the nucleotide sequence shown in SEQ ID NO:3. The present invention proves that AAV-MERTK drug treatment can significantly improve retinal pathological symptoms and restore retinal function in rats with retinitis pigmentosa caused by MERTK mutation. Intravitreal injection of AAV‑MERTK drugs can highly express MERTK in the retinal pigment epithelium and increase the thickness of the outer nuclear layer of the retina. At the same time, the electroretinogram showed that compared with the control group, the rats in the AAV‑MERTK drug treatment group responded strongly to the stimulus. Therefore, this AAV‑MERTK drug has the effect of preventing or treating retinitis pigmentosa.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.